First-in-Human trial tests 'Vaccine' to train immune system against deadly brain cancer
Disease control
Ongoing
This early-stage trial is testing a new personalized vaccine designed to treat a specific, hard-to-treat brain tumor called H3-mutated glioma. The vaccine aims to teach the patient's own immune system to recognize and attack the cancer cells. It is being given alongside standard …
Phase: PHASE1 • Sponsor: German Cancer Research Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC